A new study looked at the effect of patient genetics on their response to secukinumab, an anti-IL17 therapy commonly used to treat inflammatory conditions including arthritis and psoriasis. No link was found between a patient's genetic variants and their response to therapy. This study challenges the idea that genetics might significantly account for the variable responses to anti-IL17 therapy seen in the clinic.
to look at each patient's genetics, how they responded to treatment, and whether this revealed any common genetic patterns that could predict a good response to secukinumab. Results of the study were published in. Unfortunately, no genetic variants were found which could predict a patient's response to secukinumab.
Dr. Luke Jostins-Dean, Sir Henry Dale Fellow at the Kennedy Institute of Rheumatology and joint corresponding author on the paper, said,"These results were surprising, as it was predicted that genetics might strongly influence whether someone responds to anti-IL17 therapy.
"The results cast a doubt on whether genetics plays a role in a patient's response to anti-IL17 therapy and whether genetics could be used to predict who would benefit the most from these treatments." "Despite the negative results," said Luke,"the study adds to our deepening understanding of inflammatory andand where precision medicine can be best applied. The study also raises the question of what else could be causing the variable responses to anti-IL17 therapy, if it isn't genetics."
It is also still possible that variants exist which can predict treatment response, but they are too rare to be picked up by this study. This might be remedied by designing future GWAS studies with data from larger numbers of patients. As this was the first large GWAS study of the response to anti-IL17 therapy, it is important to understand how to best design them to find possible effects.
Danmark Seneste Nyt, Danmark Overskrifter
Similar News:Du kan også læse nyheder, der ligner denne, som vi har indsamlet fra andre nyhedskilder.
Anti-platelet therapy could help improve outcomes for patients with a deadly form of brain bleedA new study has shown that anti-platelet therapy could help improve outcomes for patients with aneurysmal subarachnoid hemorrhage (aSAH), a deadly form of brain bleed.
Læs mere »
'Bizarre' bird with supermodel legs solves 30 million-year-long mysteryIt could be a missing link.
Læs mere »
Heathrow Airport: Sadiq Khan backs proposed new rail linkThe proposed service would link the airport to south-west London, Surrey, Berkshire and Hampshire.
Læs mere »
Researchers publish consensus statement on patient selection and appropriate use of Lu-177 PSMA-617 radionuclide therapyThe Society of Nuclear Medicine and Molecular Imaging (SNMMI) has issued a new consensus statement to provide standardized guidance for the selection and management of metastatic castrate-resistant prostate cancer (mCRPC) patients being treated with 177Lu-PSMA radionuclide therapy.
Læs mere »